DuChemBio듀켐바이오
176750 · KOSDAQ · ₩176750 · 듀켐바이오
₩6,090▼ ₩310 (4.84%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | |
|---|---|---|---|---|---|---|
| Revenue | ₩11B | ₩9.7B | ₩11B | ₩9.9B | ₩9.5B | ₩8.5B |
| Cost of sales | ₩7.2B | ₩6.3B | ₩6.1B | ₩6.3B | ₩6.1B | ₩5.9B |
| Gross profit | ₩4B | ₩3.4B | ₩4.6B | ₩3.7B | ₩3.4B | ₩2.5B |
| Operating income | ₩1.9B | ₩1.3B | ₩3B | ₩1.9B | ₩1.9B | ₩670M |
| Net income | ₩332M | ₩873M | ₩5B | ₩82M | ₩975M | ₩378M |
| Net income to shareholders | ₩1.2B | ₩873M | ₩3.3B | ₩1.4B | ₩1.4B | ₩378M |
Balance sheet
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | |
|---|---|---|---|---|---|---|
| Total assets | ₩78B | ₩77B | ₩78B | ₩68B | ₩67B | ₩64B |
| Current assets | ₩33B | ₩30B | ₩29B | ₩28B | ₩26B | ₩23B |
| Cash and equivalents | ₩19B | ₩17B | ₩15B | ₩14B | ₩13B | ₩11B |
| Total liabilities | ₩26B | ₩27B | ₩28B | ₩22B | ₩22B | ₩21B |
| Current liabilities | ₩18B | ₩18B | ₩18B | ₩15B | ₩15B | ₩14B |
| Borrowings | ₩5.9B | ₩5.9B | ₩6.8B | ₩6.9B | ₩7B | ₩7.1B |
| Total equity | ₩52B | ₩50B | ₩49B | ₩46B | ₩45B | ₩43B |
| Shareholders' equity | ₩52B | ₩50B | ₩49B | ₩46B | ₩45B | ₩43B |
Cash flow
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | |
|---|---|---|---|---|---|---|
| Cash from operations | ₩3.8B | ₩3.9B | ₩2.2B | ₩2.7B | ₩2.7B | ₩2.3B |
| Capital spending | ₩123M | ₩26M | ₩248M | ₩335M | ₩230M | ₩53M |
| Free cash flow | ₩3.7B | ₩3.9B | ₩2B | ₩2.4B | ₩2.5B | ₩2.2B |
Consolidated where available. Amounts in won.
Also known as: DuChemBio / 듀켐바이오 / 176750 / KRX:176750
Source: KRX statistical information